ImmunityBio IBRX Stock
ImmunityBio Price Chart
ImmunityBio IBRX Financial and Trading Overview
| ImmunityBio stock price | 7.79 USD |
| Previous Close | 8.87 USD |
| Open | 8.92 USD |
| Bid | 6.4 USD x 200 |
| Ask | 10.31 USD x 200 |
| Day's Range | 8.05 - 8.92 USD |
| 52 Week Range | 1.95 - 12.43 USD |
| Volume | 12.78M USD |
| Avg. Volume | 13.66M USD |
| Market Cap | 8.61B USD |
| Beta (5Y Monthly) | 0.077 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13 USD |
IBRX Valuation Measures
| Enterprise Value | 9.35B USD |
| Trailing P/E | N/A |
| Forward P/E | 137 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 61.068478 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 66.35 |
| Enterprise Value/EBITDA | -38.115 |
Trading Information
ImmunityBio Stock Price History
| Beta (5Y Monthly) | 0.077 |
| 52-Week Change | 215.65% |
| S&P500 52-Week Change | 20.51% |
| 52 Week High | 12.43 USD |
| 52 Week Low | 1.95 USD |
| 50-Day Moving Average | 7.76 USD |
| 200-Day Moving Average | 5.52 USD |
IBRX Share Statistics
| Avg. Volume (3 month) | 13.66M USD |
| Avg. Daily Volume (10-Days) | 15.26M USD |
| Shares Outstanding | 1.05B |
| Float | 394.16M |
| Short Ratio | 9.91 |
| % Held by Insiders | 62.47% |
| % Held by Institutions | 17.64% |
| Shares Short | 131.83M |
| Short % of Float | 33.93% |
| Short % of Shares Outstanding | 12.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -157.87% |
| Gross Margin | 99.33% |
| EBITDA Margin | -174.079% |
Management Effectiveness
| Return on Assets (ttm) | -34.37% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 140.98M USD |
| Revenue Per Share (ttm) | 0.15 USD |
| Quarterly Revenue Growth (yoy) | 167.59% |
| Gross Profit (ttm) | 140.04M USD |
| EBITDA | -245412992 USD |
| Net Income Avi to Common (ttm) | -854534016 USD |
| Diluted EPS (ttm) | -0.79 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 380.88M USD |
| Total Cash Per Share (mrq) | 0.36 USD |
| Total Debt (mrq) | 1.12B USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.666 |
| Book Value Per Share (mrq) | -0.831 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -294390016 USD |
| Levered Free Cash Flow (ttm) | -193704624 USD |
Profile of ImmunityBio
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 3530 John Hopkins Court |
| ZIP | 92121 |
| Phone | 844 696 5235 |
| Website | https://immunitybio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 684 |
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Q&A For ImmunityBio Stock
What is a current IBRX stock price?
ImmunityBio IBRX stock price today per share is 7.79 USD.
How to purchase ImmunityBio stock?
You can buy IBRX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ImmunityBio?
The stock symbol or ticker of ImmunityBio is IBRX.
Which industry does the ImmunityBio company belong to?
The ImmunityBio industry is Biotechnology.
How many shares does ImmunityBio have in circulation?
The max supply of ImmunityBio shares is 1.05B.
What is ImmunityBio Price to Earnings Ratio (PE Ratio)?
ImmunityBio PE Ratio is now.
What was ImmunityBio earnings per share over the trailing 12 months (TTM)?
ImmunityBio EPS is -0.85 USD over the trailing 12 months.
Which sector does the ImmunityBio company belong to?
The ImmunityBio sector is Healthcare.
ImmunityBio IBRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25873.18 USD — |
-1.55
|
6.31B USD — | 25822.1 USD — | 26139.37 USD — | — - | 6.31B USD — |
|
Horizon Kinetics ISE Wealth Ind
RCH
US
|
4189.11 USD — |
-0.06
|
— — | 4162.92 USD — | 4194.53 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12700.6 USD — |
-1.53
|
— — | 12675.61 USD — | 12830.27 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3154.19 USD — |
-0.65
|
— — | 3147.71 USD — | 3174.71 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4006.39 USD — |
-1.69
|
— — | 3993.97 USD — | 4049.67 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6546.6 USD — |
-1.47
|
— — | 6508.46 USD — | 6585.47 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1254.95 USD — |
-1.05
|
— — | 1250.11 USD — | 1262.34 USD — | — - | — — |
- {{ link.label }} {{link}}